Best of AC17 Session - Novel Therapies in Lung Cancer - On-Demand

    • List Price: $35.00
    • Member Price: $25.00

Lung cancer is the leading cause of cancer-related death in the United States. With the approval of novel targeted therapies and immunotherapy, the treatment landscape for lung cancer patients has changed dramatically. The use of these agents has dramatically improved survival and quality of life in patients with advanced or metastatic non–small cell lung cancer or extensive-stage small cell lung cancer. This session will review targeted and immunotherapy agents that are used in lung cancer treatment, current guideline recommendations, and outcome data comparing these novel agents to the standard-of-care regimens.


Content Area: Patient Management & Therapeutics

Product Details:

Session from HOPA 2017 Annual Conference

Novel Therapies in Lung Cancer


Speaker: Eve Segal, PharmD BCOP


Learning Objectives:

1.      Describe the role of various signaling pathways involved in the development and progression of lung cancer.

2.   ...

Show More
There are not any reviews for this product.
Contains 0 items
Subtotal: $0.00